Literature DB >> 29221230

Neoadjuvant strategy for stage IIIA-N2 non-small cell lung cancer: chemoradiation or chemotherapy alone?

Dongrong Situ1, Yongbin Lin1,2.   

Abstract

Entities:  

Year:  2017        PMID： 29221230      PMCID： PMC5708487          DOI： 10.21037/jtd.2017.08.23

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  12 in total

Review 1.  Staging of non-small cell lung cancer: consensus, controversies and challenges.

Authors:  J P van Meerbeeck
Journal:  Lung Cancer       Date:  2001-12       Impact factor: 5.705

2.  Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.

Authors:  Miklos Pless; Roger Stupp; Hans-Beat Ris; Rolf A Stahel; Walter Weder; Sandra Thierstein; Marie-Aline Gerard; Alexandros Xyrafas; Martin Früh; Richard Cathomas; Alfred Zippelius; Arnaud Roth; Milorad Bijelovic; Adrian Ochsenbein; Urs R Meier; Christoph Mamot; Daniel Rauch; Oliver Gautschi; Daniel C Betticher; René-Olivier Mirimanoff; Solange Peters
Journal:  Lancet       Date:  2015-08-11       Impact factor: 79.321

3.  Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer.

Authors:  Michael Thomas; Christian Rübe; Petra Hoffknecht; Hans N Macha; Lutz Freitag; Albert Linder; Norman Willich; Michael Hamm; Gerhard W Sybrecht; Dieter Ukena; Karl-Matthias Deppermann; Cornelia Dröge; Dorothea Riesenbeck; Achim Heinecke; Cristina Sauerland; Klaus Junker; Wolfgang E Berdel; Michael Semik
Journal:  Lancet Oncol       Date:  2008-06-24       Impact factor: 41.316

4.  Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America.

Authors:  Nirmal K Veeramachaneni; Richard H Feins; Briana J K Stephenson; Lloyd J Edwards; Felix G Fernandez
Journal:  Ann Thorac Surg       Date:  2012-06-27       Impact factor: 4.330

Review 5.  Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer.

Authors:  Asad A Shah; Mark F Berry; Ching Tzao; Mihir Gandhi; Mathias Worni; Ricardo Pietrobon; Thomas A D'Amico
Journal:  Ann Thorac Surg       Date:  2012-06       Impact factor: 4.330

6.  Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection.

Authors:  Nichole T Tanner; Mario Gomez; Chelsea Rainwater; Paul J Nietert; George R Simon; Mark R Green; Gerard A Silvestri
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

7.  A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).

Authors:  Nobuyuki Katakami; Hirohito Tada; Tetsuya Mitsudomi; Shinzoh Kudoh; Hiroshi Senba; Kaoru Matsui; Hideo Saka; Takayasu Kurata; Yasumasa Nishimura; Masahiro Fukuoka
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

8.  Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806.

Authors:  Hideo Kunitoh; Harubumi Kato; Masahiro Tsuboi; Taro Shibata; Hisao Asamura; Yukito Ichinose; Yukito Ichonose; Nobuyuki Katakami; Kanji Nagai; Tetsuya Mitsudomi; Akihide Matsumura; Ken Nakagawa; Hirohito Tada; Nagahiro Saijo
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

9.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Authors:  Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox
Journal:  Lancet       Date:  2009-07-24       Impact factor: 79.321

10.  Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

Authors:  Wilfried Ernst Erich Eberhardt; Christoph Pöttgen; Thomas Christoph Gauler; Godehard Friedel; Stefanie Veit; Vanessa Heinrich; Stefan Welter; Wilfried Budach; Werner Spengler; Martin Kimmich; Berthold Fischer; Heinz Schmidberger; Dirk De Ruysscher; Claus Belka; Sebastian Cordes; Rodrigo Hepp; Diana Lütke-Brintrup; Nils Lehmann; Martin Schuler; Karl-Heinz Jöckel; Georgios Stamatis; Martin Stuschke
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.